These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 00469-2660
Last updated: February 19, 2026
What is NDC 00469-2660?
The National Drug Code (NDC) 00469-2660 identifies a specific prescription drug product. Based on the NDC directory, this code corresponds to Humira Pen (adalimumab), 40 mg/0.8 mL prefilled pen. It is used primarily to treat rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and other autoimmune conditions.
Approval Year: 2003 (original approval), continual extensions and label updates
Manufacture: AbbVie
Market Size and Demand
Humira remains one of the best-selling pharmaceutical products globally with peak sales reaching approximately $20.4 billion in 2021 (AbbVie Annual Report, 2022).
The drug’s status as a first-line biologic for autoimmune conditions sustains stable demand. The U.S. prescription volume for Humira was approximately 4.6 million prescriptions in 2022, with forecasted growth expected to slow due to biosimilar competition.
Competitive Landscape
Primary biosimilars: Amgen’s Amjevita, Samsung Bioepis’s Imraldi, Celltrion’s Yuflyma, and others launched between 2023-2024.
Biosomilar impact: The U.S. FDA approved the first Humira biosimilar in 2016. Biosimilars are gaining traction, with market penetration increasing yearly. By 2025, biosimilar sales globally are projected to reach $13 billion (IQVIA, 2022).
Regulatory Environment
Patent expirations: Original patents expired in the U.S. in 2023, opening markets for biosimilars.
Price controls: The U.S. federal and state policies remain market-driven; biosimilars are priced approximately 15-30% lower than originator prices, though rebates and discounts impact net prices.
Price Trends and Projections
Historical Pricing Data
Average Wholesale Price (AWP): Approximate list price is $5,800 per 40 mg/0.8 mL prefilled pen (Trade Data, 2022).
Net Price: After discounts and rebates, net prices are estimated at around $4,200-$4,600 per unit.
Current Market Price Comparison
Price Component
Approximate Value
List Price (AWP)
$5,800 per unit
Rebate/Discount
20-30% reduction from list price
Net Price
$4,200-$4,600 per unit
Price Projections (2023-2028)
Biosimilar Impact: Prices for original Humira are expected to decline as biosimilar market penetration advances. The primary biosimilars launched in late 2022 and early 2023 are expected to be priced at 15-20% less than the original.
Market Decline Forecast: As biosanilars capture market share, the price of Humira’s original product is projected to decrease by 20-30% over the next 3-5 years.
Remaining Premium for Brand: Despite biosimilar competition, original Humira may retain a pricing premium of 10-15% due to brand loyalty and formulary preferences in certain healthcare systems.
Price Outlook Summary
Year
Expected List Price (per unit)
Estimated Net Price
Biosimilar Price Range
2023
$5,800
$4,200–$4,600
$4,600–$5,000
2024
$5,300–$5,500
$3,800–$4,400
$4,200–$4,700
2025
$4,900–$5,300
$3,500–$4,100
$3,900–$4,300
2026
$4,700–$5,000
$3,300–$3,800
$3,700–$4,000
2027
$4,500–$4,800
$3,100–$3,500
$3,500–$3,700
Market Risks and Opportunities
Risks
Accelerated biosimilar approval and uptake.
Changing U.S. pricing and reimbursement policy.
Patent litigation delaying biosimilar entry.
Opportunities
Increased adoption in emerging markets.
Label expansions for additional indications.
Potential for biosimilars to lower the cost of treatment further, leading to expanded use.
Key Takeaways
Humira (NDC 00469-2660) maintains significant market share due to its broad indications.
Original brand prices have declined but remain substantial in absolute terms.
Biosimilar competition will lead to further price reductions, with a potential 20-30% decrease over the next five years.
Pricing varies significantly based on discounts, rebates, and regional market conditions.
The landscape remains dynamic, with regulatory and patent challenges influencing future pricing trends.
FAQs
What factors influence Humira’s price declines? Patent expirations, biosimilar approvals, reimbursement policies, and market competition drive prices downward.
How much are biosimilars expected to cost compared to the original? Biosimilars are priced approximately 15-20% below the original brand, with some variations.
What regions will see the most price reductions? The U.S. will experience the steepest decline due to biosimilar competition; emerging markets may see slower price declines.
What is the outlook for Humira’s market share? Original Humira’s market share is expected to decline gradually, with biosimilars capturing a significant portion of prescription volume.
Are there opportunities for new indications to affect pricing? Yes, label expansions could sustain or increase demand, counterbalancing price pressures.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
